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Letters to the Editor to count as a near-universal belief. If so, I think his worry is misplaced. "The vagueness of near-universal does not imply that claims about a near-universal belief cannot be true." The claim that there is a lot of sugar in the pudding is vague but can be true or false.) The important issue, of course, is whether reductionism is a view that is dominant in psychiatry-whether it motivates theory, affects treatment, and drives research. I hardly think that anyone could deny this. If the minority of psychiatrists who are anti-reductionists is, in fact, growing, I can only welcome the news that there is less work to do than I had thought.
Ian Gold, PhD Montreal, Quebec

The Absence of a Placebo Group Is a Serious Limitation of the STAR*D Trial
Dear Editor: Given the complexity of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, we appreciated Sinyor et al's 1 lucid review. The absence of a placebo group, however, is a serious limitation of STAR*D that deserved greater emphasis, particularly in light of recent meta-analyses of randomized controlled trials (RCTs) of antidepressants (ADs). [2] [3] Although we agree that "inclusion of a placebo arm would have meant a departure from the principle of pragmatism," 1, p 134 the existing evidence did not justify such a purely pragmatic trial. Comparing active treatments without a placebo group is appropriate when at least one of the treatments has established benefits, but according to the metaanalyses cited, ADs have little or no benefit compared with placebo for mild to moderate depression. This has particular implications for STAR*D, which included many mildly depressed patients.
We recognize that the findings of the meta-analyses are controversial. Even if these studies are set aside, however, it remains that the superiority of ADs over placebo has not been established in depressed patients who are treated not in standard RCTs but in the real-world settings of STAR*D. The absence of a placebo group may improve STAR*D's generalizability to clinical practice, but the considerable cost is that the trial provides little information about the effectiveness of the treatments in this context. Indeed, given the striking result that no differences were found between medications with completely different mechanisms of action, it is likely that nonspecific factors-such as the placebo effect and the experience of being in treatment-were much more important than the specific treatments themselves. Further, as depression is typically an episodic illness that remits on its own within a year, 4 and STAR*D lasted about a year for patients who progressed to the end of the fourth treatment level, it is difficult to interpret the cumulative 67% remission rate in patients who remained in the study. The meaning of this figure becomes even less clear when one considers that many patients dropped out of the study or relapsed during the 12-month naturalistic follow-up.
The authors conclude that the results of STAR*D "have shed important light on the effectiveness of current treatment strategies for patients with depression." 1, p 134 However, we would argue that because of the absence of a placebo group, STAR*D obscures more than it illuminates. In fact, the very decision not to include a placebo group implies that the benefits of ADs are better established than current evidence suggests.
Daniel A Gorman, MD, FRCPC Elia Abi-Jaoude, MSc, MD, FRCPC Toronto, Ontario
Reply..
Re: The Absence of a Placebo Group Is a Serious Limitation of the STAR*D Trial
Dear Editor:
We would like to thank Dr Gorman and Dr Abi-Jaoude for their letter. It provides us with an important opportunity to clarify the distinction between pragmatic and explanatory trials. Explanatory trials are designed to test whether a specific treatment has added benefit over placebo in a homogenous patient population. In contrast, pragmatic trials are designed to test how a heterogeneous, more typical patient population responds to interventions under a closer approximation of the conditions found in clinical practice, that is, in the real world.
In any trial design there are tradeoffs and STAR*D's pragmatic design, omitting a placebo arm, did not allow authors to ask the question of whether it was a failed trial; that is, were all treatments equally effective or equally ineffective. However, this does not interfere with our ability to interpret the results. STAR*D provides clinically relevant benchmarks for treatment response at each level in addition to a host of important secondary outcomes. Dr Gorman and Dr Abi-Jaoude state that
